Comparative analysis of the effectiveness of assisted reproductive technology in oncology patients
- Authors: Dobrokhotova Y.E.1, Lapina I.A.1,2, Malakhova A.A.1,2, Chirvon T.G.1, Gomzikova V.M.1, Sorokin Y.A.2
-
Affiliations:
- Russian National Research Medical University named after N.I. Pirogov
- Clinical and Diagnostic center MEDSI
- Issue: Vol 12, No 1 (2025)
- Pages: 116-124
- Section: Original study articles
- URL: https://journal-vniispk.ru/2313-8726/article/view/310014
- DOI: https://doi.org/10.17816/aog646303
- ID: 310014
Cite item
Abstract
BACKGROUND: The annual increase in the number of oncology patients and improvements in their quality of life are among the top priorities of modern medicine. Gonadotoxic treatments lead to premature ovarian insufficiency and infertility. To address this issue, various assisted reproductive technologies (ART) have been developed. First-line approaches for fertility preservation involve oocyte and embryo vitrification. Ovarian stimulation and in vitro maturation (IVM) of oocytes are used to achieve this goal.
AIM: To assess the effectiveness of different ART methods for preserving reproductive material in oncology patients.
MATERIALS AND METHODS: A prospective study was conducted with 48 women of reproductive age diagnosed with oncological diseases. In the first stage, fertility preservation potential was assessed. After stratifying the patients into groups, ovarian stimulation followed by transvaginal oocyte retrieval was performed, or immature oocytes were obtained for in vitro maturation. The collected material was then assessed by an embryologist, who carried out fertilization and vitrification.
RESULTS: The average age of the patients was 33.9±1.7 years, anti-Müllerian hormone levels ranged from 1.26 to 3.02 ng/mL, and the number of antral follicles was approximately 10. In the first group, 256 oocyte-cumulus complexes were retrieved, with 73.0% of them being mature. In the second group, 149 complexes were obtained, with 38.9% suitable for vitrification. Structural abnormalities were more commonly observed in the oocytes matured in vitro. The number of embryos obtained was 161 and 78 in the first and second groups, respectively.
CONCLUSION: Fertility preservation in oncology patients remains a critical challenge in modern healthcare. Ovarian stimulation shows high efficiency in obtaining reproductive material. The in vitro maturation method should be used only as an alternative to ovarian stimulation or in cases of high ovarian reserve.
Full Text
##article.viewOnOriginalSite##About the authors
Yulia E. Dobrokhotova
Russian National Research Medical University named after N.I. Pirogov
Email: pr.dobrohotova@mail.ru
ORCID iD: 0000-0002-7830-2290
SPIN-code: 2925-9948
MD, Dr. Sci. (Medicine), Professor
Russian Federation, 1 Ostrovityanova st, Moscow, 117997Irina A. Lapina
Russian National Research Medical University named after N.I. Pirogov; Clinical and Diagnostic center MEDSI
Email: doclapina@mail.ru
ORCID iD: 0000-0002-2875-6307
SPIN-code: 1713-6127
MD, Dr. Sci. (Medicine), Professor
Russian Federation, 1 Ostrovityanova st, Moscow, 117997; MoscowAnastasiya A. Malakhova
Russian National Research Medical University named after N.I. Pirogov; Clinical and Diagnostic center MEDSI
Author for correspondence.
Email: anastasimed@yandex.ru
ORCID iD: 0000-0002-2140-8000
SPIN-code: 2668-1696
Assistant
Russian Federation, 1 Ostrovityanova st, Moscow, 117997; MoscowTatiana G. Chirvon
Russian National Research Medical University named after N.I. Pirogov
Email: tkoltinova@gmail.com
ORCID iD: 0000-0002-8302-7510
SPIN-code: 9582-1650
MD, Cand. Sci. (Medicine)
Russian Federation, 1 Ostrovityanova st, Moscow, 117997Valeriia M. Gomzikova
Russian National Research Medical University named after N.I. Pirogov
Email: gomzval1402@gmail.com
ORCID iD: 0000-0001-6297-8811
Postgraduate Student
Russian Federation, 1 Ostrovityanova st, Moscow, 117997Yury A. Sorokin
Clinical and Diagnostic center MEDSI
Email: sorokin_y@mail.ru
ORCID iD: 0000-0001-9305-323X
Department Head
Russian Federation, MoscowReferences
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834
- Jayasinghe YL, Wallace WHB, Anderson RA. Ovarian function, fertility and reproductive lifespan in cancer patients. Expert Rev Endocrinol Metab. 2018;13(3):125–136. doi: 10.1080/17446651.2018.1455498
- Hagege E, Sokteang S, Ayoubi JM, de Ziegler D. Fertility preservation counseling: old indications, novel perspectives. Fertility and Sterility. 2024;121(4):553–554. doi: 10.1016/j.fertnstert.2024.01.004
- Krasnopolsky VI, Krasnopolskaya KV, Nazarenko TA, et al. Methods of preserving genetic material for delayed realization of reproductive function in patients with or who have undergone oncological diseases: Information and methodological letter. Moscow; 2015. 20 р. (In Russ.)
- Krasnopolskaya KV, Nazarenko TA, Sesina NI, Zakharchenko EO. Reproductive medicine in cancer patients: what is real? P.A. Herzen Journal of Oncology. 2018;7(1):68–74. doi: 10.17116/onkolog20187168-74 EDN: YRTONG
- Krasnopolskaya KV, Novikova OV, Shevchyuk AS, et al. Reproductive function in cancer patients. Gynecologic Oncology. 2021;(3):49–56. doi: 10.52313/22278710_2021_3_49 EDN: YGUDEF
- Cryostorage of reproductive tissues in the in vitro fertilization laboratory: a committee opinion. Fertility and Sterility. 2020;114(3):486–491. doi: 10.1016/j.fertnstert.2020.06.019
- Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion / Practice Committee of the American Society for Reproductive Medicine. Fertility and Sterility. 2019;112(6):1022–1033. doi: 10.1016/j.fertnstert.2019.09.013
- Clinical guidelines for “Female infertility”. Ministry of Health of the Russian Federation; 2024. 90 р. (In Russ.)
- Rodriguez-Wallberg KA, Hao X, Marklund A, et al. Hot topics on fertility preservation for women and girls-current research, knowledge gaps, and future possibilities. J Clin Med. 2021;10(8):1650. doi: 10.3390/jcm10081650
- ESHRE Guideline Group on Female Fertility Preservation, Anderson RA, Amant F, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052. doi: 10.1093/hropen/hoaa052
- Plancha CE, Rodrigues P, Marques M, et al. The time is ripe for oocyte in vitro maturation. J Assist Reprod Genet. 2021;38(6):1281–1283. doi: 10.1007/s10815-021-02209-x
- Yang ZY, Chian RC. Development of in vitro maturation techniques for clinical applications. Fertility and Sterility. 2017;108(4):577–584. doi: 10.1016/j.fertnstert.2017.08.020
- Gong X, Li H, Zhao Y. The improvement and clinical application of human oocyte in vitro maturation (IVM). Reprod Sci. 2022;29(8):2127–2135. doi: 10.1007/s43032-021-00613-3
- Martinez F; International Society for Fertility Preservation–ESHRE–ASRM Expert Working Group. Update on fertility preservation from the Barcelona International Society for Fertility Preservation–ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives. Fertility and Sterility. 2017;108(3):407–415.e11. doi: 10.1016/j.fertnstert.2017.05.024
- Bunyaeva ES, Kirillova AO, Nazarenko TA, et al. Indications and effectiveness of technique for immature oocyte-cumulus complexes retrieval from ovarian tissue followed by their in vitro maturation. Akusherstvo i Ginekologiya. 2022;(6):75–82. doi: 10.18565/aig.2022.6.75-82 EDN: JTACOS
- Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. doi: 10.1200/JCO.2018.78.1914
- Mostinckx L, Goyens E, Mackens S, et al. Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF/ICSI. Hum Reprod. 2024;39(3):586–594. doi: 10.1093/humrep/dead273
- Seok HH, Song H, Lyu SW, et al. Application of serum anti-Müllerian hormone levels in selecting patients with polycystic ovary syndrome for in vitro maturation treatment. Clin Exp Reprod Med. 2016;43(2):126–132. doi: 10.5653/cerm.2016.43.2.126
- Cohen Y, Tannus S, Volodarsky-Perel A, Son WY, Tulandi T, Buckett W. Added benefit of immature oocyte maturation for fertility preservation in women with malignancy. Reprod Sci. 2020;27(12):2257–2264. doi: 10.1007/s43032-020-00245-z
- Virant-Klun I, Bedenk J, Jancar N. In vitro maturation of immature oocytes for fertility preservation in cancer patients compared to control patients with fertility problems in an in vitro fertilization program. Radiol Oncol. 2021;56(1):119–128. doi: 10.2478/raon-2021-0053
- Creux H, Monnier P, Son WY, Buckett W. Thirteen years’ experience in fertility preservation for cancer patients after in vitro fertilization and in vitro maturation treatments. J Assist Reprod Genet. 2018;35(4):583–592. doi: 10.1007/s10815-018-1138-0
Supplementary files
